Enveric Biosciences, a biotechnology company dedicated to the development of neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, has completed manufacturing of drug material enabling the completion of preclinical work for EB-373 including all bioanalytical method validation, GLP toxicology and GLP safety pharmacology studies. Enveric will immediately commence remaining GLP studies to provide critical data required to initiate human tria...